ICU Medical, Inc. (NASDAQ:ICUI) Shares Sold by Silvercrest Asset Management Group LLC

Silvercrest Asset Management Group LLC decreased its holdings in shares of ICU Medical, Inc. (NASDAQ:ICUI) by 5.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 358,386 shares of the medical instruments supplier’s stock after selling 22,217 shares during the quarter. Silvercrest Asset Management Group LLC owned approximately 1.46% of ICU Medical worth $55,611,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of ICUI. Norges Bank acquired a new stake in ICU Medical during the fourth quarter worth about $40,151,000. Point72 Asset Management L.P. raised its stake in ICU Medical by 63.2% during the fourth quarter. Point72 Asset Management L.P. now owns 245,340 shares of the medical instruments supplier’s stock worth $38,069,000 after acquiring an additional 95,030 shares during the period. Dimensional Fund Advisors LP raised its stake in ICU Medical by 18.2% during the fourth quarter. Dimensional Fund Advisors LP now owns 539,981 shares of the medical instruments supplier’s stock worth $83,788,000 after acquiring an additional 82,982 shares during the period. Raymond James Financial Inc. acquired a new stake in ICU Medical during the fourth quarter worth about $10,003,000. Finally, JPMorgan Chase & Co. raised its stake in ICU Medical by 7.4% during the fourth quarter. JPMorgan Chase & Co. now owns 708,382 shares of the medical instruments supplier’s stock worth $109,920,000 after acquiring an additional 49,108 shares during the period. Institutional investors and hedge funds own 96.10% of the company’s stock.

Insider Buying and Selling

In related news, Director David C. Greenberg sold 1,942 shares of the firm’s stock in a transaction that occurred on Tuesday, May 13th. The shares were sold at an average price of $143.66, for a total value of $278,987.72. Following the completion of the transaction, the director now owns 6,760 shares of the company’s stock, valued at approximately $971,141.60. This trade represents a 22.32% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Ben Sousa sold 2,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 15th. The stock was sold at an average price of $137.36, for a total transaction of $274,720.00. Following the completion of the transaction, the insider now directly owns 479 shares of the company’s stock, valued at $65,795.44. This represents a 80.68% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 15,053 shares of company stock worth $2,077,027. Corporate insiders own 1.50% of the company’s stock.

ICU Medical Trading Up 3.4%

ICU Medical stock opened at $140.54 on Friday. The stock has a market capitalization of $3.46 billion, a PE ratio of -30.75 and a beta of 0.87. ICU Medical, Inc. has a 12-month low of $100.91 and a 12-month high of $196.26. The company has a debt-to-equity ratio of 0.75, a current ratio of 2.29 and a quick ratio of 1.03. The firm has a 50 day simple moving average of $140.80 and a 200-day simple moving average of $154.33.

ICU Medical (NASDAQ:ICUI) last issued its earnings results on Thursday, May 8th. The medical instruments supplier reported $1.72 earnings per share for the quarter, topping analysts’ consensus estimates of $1.23 by $0.49. The firm had revenue of $599.49 million during the quarter, compared to analysts’ expectations of $574.15 million. ICU Medical had a negative net margin of 4.74% and a positive return on equity of 5.05%. The firm’s revenue for the quarter was up 6.7% compared to the same quarter last year. During the same period last year, the firm posted $0.96 earnings per share. As a group, equities research analysts expect that ICU Medical, Inc. will post 4.11 EPS for the current fiscal year.

Analyst Ratings Changes

ICUI has been the subject of several recent analyst reports. KeyCorp decreased their target price on shares of ICU Medical from $209.00 to $191.00 and set an “overweight” rating for the company in a research report on Monday, April 21st. Raymond James decreased their target price on shares of ICU Medical from $197.00 to $187.00 and set a “strong-buy” rating for the company in a research report on Friday, May 9th. Needham & Company LLC restated a “hold” rating on shares of ICU Medical in a research report on Tuesday, April 8th. Finally, StockNews.com cut shares of ICU Medical from a “buy” rating to a “hold” rating in a research report on Saturday, May 10th. Two investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, ICU Medical currently has a consensus rating of “Moderate Buy” and an average price target of $192.67.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.